NUAK1

Across TCGA pan-cancer cohorts, NUAK1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NUAK1 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NUAK1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NUAK1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where NUAK1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.273	0.748	.008	30	view →
LSCC	DFS	Quartile	II,III,IV	0.557	0.927	.029	4	view →
LUAD	OS	Median	II,III,IV	1.000	0.651	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NUAK1–PDAC (OS)

Open the PDAC breakdown →